ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2916

Analysis of Risk Factors of the Progression to Chronic Kidney Disease and Comorbidities in Lupus Nephritis

Yoichiro Akiyama, Takeo Sato, Takamasa Murosaki, Katsuya Nagatani, Masahiro Iwamoto and Seiji Minota, Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Chronic disease care, Lupus nephritis, prognostic factors and proteinuria

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Many studies have reported long-term outcomes including morbidity, mortality, and end stage kidney disease (ESKD) in patients with lupus nephritis (LN). We aimed to elucidate the risk factor of the progression to chronic kidney disease (CKD) in patients with lupus nephritis, and the development of comorbidity and its impact on the renal function.

Methods: We collected 116 patients with a diagnosis of LN who were hospitalized in our division from 2005 to 2013, and were followed up for at least 1 year or died within 1 year. We retrospectively examined the demographics, the clinical course, and the progression to CKD (defined as equal to or severer than G3bA1, G3aA2, or G2A3 by the classification for CKD). We performed COX hazard regression analysis to elucidate the risk factor of the progression to CKD and examined the impact of acute kidney injury (AKI) and acute decompensated heart failure (ADHF) on the renal function and the incidence of vascular event.

Results: The ratio of female to male was 8.7 : 1 and the median age of LN onset was 32 year-old. LN as one of the first symptoms was 54%, and 52% of LN showed proteinuria ≥ 3.5 g/day at least one time during the clinical course. Clinical symptoms and laboratory data included arthritis or arthralgia (41%), facial erythema (40%), serositis (20%), neurological symptoms (12%), hematological abnormality (22%), positive anti-double stranded DNA antibody (86%), and positive anti-phospholipid antibody (30%). In 98 renal biopsy-proven patients (86%), the pathological diagnoses (WHO classification) were class II (7%), IV (III) (45%), V (32%), and IV (III)+V (16%). Kaplan-Meier analysis showed survival, ESKD (introduction of dialysis or renal transplantation)-free, and CKD-free rate at 20 years were 0.761, 0.677, and 0.433, respectively (Figure 1). Multivariate COX hazard regression analysis revealed the hazard ratio of proteinuria ≥ 3.5 g/day for the progression to CKD was 2.01 (95% confidence interval, 1.06 to 3.81; p = 0.03). ADHF, AKI, and vascular events developed in 6, 9, and 12 patients, respectively. All patients with ADHF and 8 of 9 patients with AKI progressed to CKD eventually. There was a tendency that the cumulative incidence of vascular events in patients with CKD was higher than in those with non-CKD in the late phase (0.45 vs. 0.24, Figure 2). 

Conclusion: Nephrotic proteinuria was a risk factor of CKD, and ADHF and AKI may have a deteriorating impact on the subsequent renal function. In the late phase, vascular events should be cared for patients with LN who progressed to CKD.


Disclosure: Y. Akiyama, None; T. Sato, None; T. Murosaki, None; K. Nagatani, None; M. Iwamoto, Astellas Pharma, 8,Takeda Phamaceutical, 8; S. Minota, Astellas, 2,Pfizer Inc, 2,Essai, 2,AbbVie, 2,Mitsubishi-Tanabe, 2,Takeda, 2,Chugai, 7.

To cite this abstract in AMA style:

Akiyama Y, Sato T, Murosaki T, Nagatani K, Iwamoto M, Minota S. Analysis of Risk Factors of the Progression to Chronic Kidney Disease and Comorbidities in Lupus Nephritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/analysis-of-risk-factors-of-the-progression-to-chronic-kidney-disease-and-comorbidities-in-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-risk-factors-of-the-progression-to-chronic-kidney-disease-and-comorbidities-in-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology